It’s not new news that the much-maligned Cities: Skylines II did not manage to come close to the success of the first game in the series. Colossal Order and Paradox Interactive’s difficult second ...
Knoepfler is STAT’s Lab Dish columnist and a professor of cell biology and human anatomy at UC Davis School of Medicine. De-extinction firm Colossal Biosciences announced Tuesday that it was acquiring ...
This business acquisition appears to be a genetic match: Colossal Biosciences, the company that brought back the dire wolves, has acquired Viagen Pets and Equine, which has cloned dogs for Paris ...
ViaGen has successfully cloned endangered species like Przewalski’s horses. Elizabeth Arellano Photography/Courtesy Colossal Biosciences However, Colossal CEO Ben Lamm insists the move wasn’t ...
AUSTIN (KXAN) — An Austin-based company was acquired by Colossal Biosciences, a biosciences company that has claimed to “de-extinct” animals, according to a Tuesday announcement. Viagen Pets and ...
Colossal Biosciences has made its first acquisition since its 2021 launch. Now valued at more than $10 billion, the de-extinction company has acquired Viagen Pets and Equine, an Austin-based animal ...
‘De-extinction’ startup Colossal Biosciences makes its first acquisition: a company that clones pets
The cloning industry is contracting—ironically, perhaps. On Tuesday, Colossal Biosciences announced that it has acquired ViaGen Pets and Equine, an animal cloning firm, marking Colossal’s first ...
CHICAGO (WLS) -- More than 50,000 people will line up Sunday morning for a 26.2-mile tour of Chicago, on foot, and they pay money for the privilege. The 47th running of the Bank of America Chicago ...
Last week de-extinction company, Colossal Biosciences, announced it is one step closer to reviving the dodo bird. The breakthrough achievement comes after the company successfully grew pigeon ...
A rendering of the dodo, one of the extinct species Colossal Biosciences is attempting to bring back. Courtesy Colossal Biosciences Extinction is supposed to be permanent. But Colossal Biosciences, a ...
Colossal Biosciences genome engineer Jonathan Walsh works on thylacine projects during a tour of the facility, on Friday, Jan. 17, 2025 in Dallas. Shafkat Anowar / Staff Photographer Science startup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback